综述:肿瘤坏死因子拮抗剂在炎症性肠病患者中引起的矛盾性银屑病
本文综述了皮肤病学与胃肠病学文献中关于炎症性肠病(IBD)患者使用肿瘤坏死因子(TNF)拮抗剂后出现的矛盾性银屑病的证据。矛盾性银屑病被认为是TNF拮抗剂治疗的一种矛盾效应,银屑病皮损常出现于治疗第一年内;其发病机制可能与炎症细胞因子失衡有关,组织学表现虽类似经典银屑病但具有独特特征。治疗选择应基于皮肤病变严重程度、基础IBD活动度及患者个体临床病史,并建议多学科团队共同讨论。
要点
- 矛盾性银屑病是TNF拮抗剂治疗IBD的一种矛盾效应,皮损常出现于治疗第一年内。
- 其发病机制可能与炎症细胞因子失衡有关,组织学表现类似经典银屑病但有独特特征。
- 治疗选择应基于皮肤病变严重程度、IBD活动度及患者个体临床病史。
核心结论
- 矛盾性银屑病被认为是TNF拮抗剂治疗的一种矛盾效应,可导致银屑病皮损,常出现于治疗第一年内。
- 其发病机制尚未完全阐明,可能与炎症细胞因子失衡有关。
- 组织学表现虽类似经典银屑病,但具有独特特征。
- 临床表现因人而异,但常出现于IBD维持治疗期间。
- 治疗选择应基于皮肤病变严重程度、基础IBD活动度及患者个体临床病史。
研究设计与样本
- 本文为综述,通过PubMed进行文献检索,纳入呈现、讨论或总结IBD个体中矛盾性银屑病相关数据的稿件。
主要发现
- 矛盾性银屑病常出现于TNF拮抗剂治疗第一年内。
- 发病机制尚未完全阐明,可能与炎症细胞因子失衡有关。
- 组织学表现类似经典银屑病,但具有独特特征。
- 临床表现因人而异,但常出现于IBD维持治疗期间。
临床怎么用
- 治疗选择应基于皮肤病变严重程度、基础IBD活动度及患者个体临床病史。
- IBD中矛盾性银屑病的处理应与多学科团队讨论,以优化并维持肠道疾病缓解,并确保严重皮肤病变的消退。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumour necrosis factor (TNF) antagonists are an efficacious therapy used in the management of several immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD) and psoriasis. However, since being prescribed more widely, reports of new-onset psoriatic lesions have began to emerge in the literature and are known as paradoxical psoriasis. AIM: To review the evidence available in both the dermatology and gastroenterology literature pertaining to the entity known as paradoxical psoriasis as it relates to IBD and to create a comprehensive guide to assist clinicians who treat this challenging patient population. METHODS: A literature search was conducted in PubMed to identify manuscripts that presented, discussed or summarised data pertaining to paradoxical psoriasis presenting in individuals with IBD. RESULTS: Paradoxical psoriasis is now thought to be a contradictory effect of TNF antagonist therapy leading to psoriatic lesions often within the first year of treatment. The underlying pathogenesis, although not completely understood, is likely related to an imbalance of inflammatory cytokines. The histological appearance, while similar to classical psoriasis, does have unique features. The clinical presentation can vary among patients but often presents during maintenance therapy for inflammatory bowel disease. Treatment options should be determined based upon the severity of the skin lesion, activity of the underlying inflammatory bowel disease and the patient's unique clinical history. CONCLUSIONS: The approach to paradoxical psoriasis in IBD should be discussed with a multidisciplinary team to optimise and preserve intestinal disease remission and to ensure the resolution of debilitating skin lesions.
引用
- Townsend CM, Lovegrove F, Khanna R, et al. Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022. PMID: 35312094. doi:10.1111/apt.16883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。